Pith. sign in

REVIEW 2 major objections 5 minor 14 references

Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy

T0 review · 2 major / 5 minor · reviewed 2026-08-10 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Patient activation after BNCT stays far below the iodine-131 discharge threshold.

desk verdict Useful facility-level radiation protection study with a clean Monte Carlo benchmark, but the discharge conclusion leans on an administrative threshold rather than a dose limit. read the letter →

arxiv 2501.13053 v1 pith:C23SCZOK submitted 2025-01-22 physics.med-ph

Giovanni Garini , Chiara Magni , Ian Postuma , Setareh Fatemi , Ricardo Ramos , Barbara Marcaccio , Cristina Pezzi , Laura Bagnale
show 5 more authors
Sandro Sandri Gianfranco De Matteis Giuseppe Paolisso Valerio Vercesi Silva Bortolussi
This is my paper · ORCID
classification physics.med-ph
keywords BoronNeutronCaptureTherapypatientactivationradiationprotectiondosimetryambientdoseMonteCarlosimulationurinedischarge
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper sets out to show that patients treated with Boron Neutron Capture Therapy do not become radioactive enough to be a radiation hazard to staff or family, and can therefore be discharged soon after irradiation. Since no regulation specifically covers neutron-irradiated patients, the authors propose a practical criterion: compare the ambient dose around the treated patient with the ambient dose from a patient carrying 600 MBq of iodine-131, the activity above which Italian rules require hospitalisation. Using a standard adult computational phantom and two Monte Carlo transport codes, they find that even a deliberately conservative 2-hour irradiation leaves the patient's ambient dose rate roughly two orders of magnitude below that benchmark. On the same basis, they conclude that early patient discharge, possibly as soon as 15 minutes after beam shutdown, is feasible.

What carries the argument

The load-bearing mechanism is a comparison of ambient dose-rate maps: the $H^{*}$ field around the BNCT-activated patient is compared with the $H^{*}$ field produced by 600 MBq of $^{131}$I localised in the thyroid. These maps are built with a chain of standard tools: an adult mesh-type reference phantom, a Monte Carlo particle-transport code benchmarked against a second transport code, an activation-chain solver that converts simulated neutron fluence into decay sources, and tabulated conversion factors from photon fluence to ambient dose. The same chain is applied to urine activation, after correcting the phantom's urine composition to include chlorine and sulphur, which are the elements driving short- and long-lived activity.

What would settle it

Measure the ambient dose-rate profile around a real BNCT patient 15 minutes after a 2-hour irradiation; if the value at 30-40 cm from the body exceeds the corresponding $H^{*}$ from 600 MBq of $^{131}$I in the thyroid (about $1.15 \times 10^{3}$ µSv/h), the proposed discharge criterion is contradicted.

Watch

Extended reading notes

Core claim

The central claim is that, under a conservative 2-hour BNCT irradiation, patient activation does not pose a significant radiological concern, and that a patient could be discharged about 15 minutes after treatment. The paper defends this by introducing a figure of merit borrowed from nuclear medicine: since current Italian legislation only mandates post-treatment hospitalisation for patients administered more than 600 MBq of iodine-131, the authors take the ambient dose from that amount of iodine-131 concentrated in the thyroid as the acceptable upper bound. Simulating an adult patient irradiated in three representative districts (head-neck, thorax, lower limbs) with two cross-checked transport codes, they obtain ambient dose rates around the activated patient that are about two orders of magnitude lower than the iodine-131 reference at all distances. The same simulations show that the patient's urine becomes activated enough to require shielded collection and decay storage, a finding that directly affects facility design.

Load-bearing premise

The load-bearing premise is that a BNCT patient is safe to be near whenever their ambient dose is below that of a patient carrying 600 MBq of iodine-131 in the thyroid; that threshold comes from a regulatory hospitalisation rule for radiopharmaceutical patients, not from a measured dose limit for neutron-activated people.

Editorial extensions

If this is right

  • Staff can be allowed into the treatment room about 15 minutes after beam shutdown without exceeding the proposed safety benchmark.
  • Patients treated with BNCT may be eligible for discharge shortly after treatment, reducing the need for in-patient radioactive-isolation beds.
  • Facility designers must still include a shielded hot restroom and controlled decay storage because activated urine needs to be collected and held.
  • After roughly ten days, urine radioactivity is dominated by the long-lived isotopes $^{35}$S and $^{40}$K, which sets the waste-management timeline.
  • The agreement between the two transport codes supports using the faster code for future facility-specific activation estimates.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The same comparison criterion could be translated into other regulatory systems by substituting the local discharge threshold for the Italian 600 MBq iodine-131 level.
  • A prospective measurement campaign on real BNCT patients could test the model's predictions directly: the calculated 15-minute contact-distance dose rates of roughly 50-60 µSv/h are easy to check with a survey meter.
  • The safety margin of about a factor of twenty could shrink if irradiation time, beam energy, or patient composition changes substantially, so the criterion should be re-evaluated for each treatment protocol.
  • The urine-activation results imply that shielded plumbing and waste storage are essential design constraints even if patients leave quickly, an operational consequence the paper begins to quantify.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

2 major / 5 minor

Summary. This paper presents a computational study of patient activation after Boron Neutron Capture Therapy (BNCT) for the planned ANTHEM accelerator-based facility in Italy. Using the ICRP-145 adult mesh phantom, the authors benchmark the Monte Carlo codes MCNP6.3 and PHITS3.33 for a 600 MBq 131I source in the thyroid, then apply PHITS with DCHAIN-SP to compute activation of organs and ambient dose rates (H*) around the patient for three irradiation sites (head/neck, thorax, lower limbs) and irradiation times of 1 and 2 hours. They propose a discharge criterion that equates the ambient dose from the activated BNCT patient to that of a patient administered with 600 MBq 131I, referencing Italian Legislative Decree 101/2020. The computed H* rates after 15 minutes post-irradiation are roughly one to two orders of magnitude below the 131I reference, leading the authors to suggest that patient discharge could occur as early as 15 minutes after treatment. The paper also evaluates the activation of urine and discusses implications for facility design.

Significance. If the proposed criterion is accepted, the results would support early patient discharge after BNCT, a practically important outcome for accelerator-based BNCT centers. The paper is valuable for its careful code-to-code benchmark, its use of the modern ICRP-145 phantom, and its explicit reporting of statistical uncertainties on all tallied quantities. The main limitation is that the discharge criterion is an assumption (the 600 MBq 131I hospitalization threshold is an administrative rule for nuclear medicine, not a dose limit for family or staff), and the manuscript does not compute effective doses to contact persons or compare with the 1 mSv/y public dose constraint. The authors acknowledge this in the final paragraph of the Conclusions, but the abstract states the unconditional claim. A second gap is that the activation inventory from PHITS/DCHAIN-SP is not validated against independent calculations or measurements. These issues make the central safety claim conditional, but the underlying computational results remain a useful contribution to radiation protection design.

major comments (2)
  1. [Section 2 (page 4); Section 3.4 (page 18); Conclusions (page 21)] The proposed discharge criterion in Section 2 states that 'below this threshold, contact with a treated patient is safely acceptable' because Italian Legislative Decree 101/2020 mandates hospitalization only for administered activities greater than 600 MBq of 131I. This equivalence is an assumption, not an established dose limit; the 600 MBq value is an administrative criterion for hospital admission in unsealed-source therapy, and it does not directly correspond to a public or family effective dose constraint. The paper does not convert the measured H* rates into effective doses for realistic contact scenarios (e.g., a family member sleeping in the same bed, staff assisting the patient, or public waiting areas) nor compare those doses with the 1 mSv/y public dose limit or ICRP/NCRP release criteria. Consequently, the conclusions that 'patient activation does not pose a significant radiological concern' and that discharge 'possibly as soon as 15 minutes' is possible are not entailed by the computed dose rates alone; they hold only if the 131I equivalence is accepted as a safety limit. The last paragraph of the Conclusions acknowledges the need for future validation, but the abstract and the main conclusions should be tempered accordingly, or the authors should provide an independent dose assessment.
  2. [Section 3.1 (page 8) and Section 3.3 (pages 10-17)] The benchmark in Section 3.1 validates PHITS against MCNP only for the 131I-in-thyroid source, i.e., for photon transport from a fixed source. The patient activation calculations in Section 3.3 rely entirely on PHITS with DCHAIN-SP for neutron-induced activation and decay, and no independent validation of the activation inventory is presented. The H* rates in Tables 7, 11, and 15 and the urine activities in Tables 17 and 18 therefore carry an unquantified systematic uncertainty from the activation code and nuclear data libraries. To support the quantitative conclusions, the authors should benchmark the activation calculation (e.g., against MCNP with a depletion/burnup code or against measured activation data from an existing accelerator-based BNCT facility), or explicitly state this as a limitation in the abstract and conclusions.
minor comments (5)
  1. [Section 3.4 (page 18)] The statement that the difference is 'almost of two order of magnitude' is inaccurate: from Table 16, the ratio of the 131I H* to the head/neck value at 30-40 cm is 1150/53.3 ≈ 21.6, which is slightly more than one order of magnitude, not two. Please correct this quantitative description.
  2. [Tables 2, 3, 7, 11, 15] Units are inconsistent across tables: Table 2 reports H* in pSv·s−1 while Tables 3, 7, 11, and 15 use µSv/h, and the text in Section 3.4 compares values that are not all in the same units. Please harmonize units in all tables and figures.
  3. [Section 2.2 (page 6)] The wall composition is described as 'previously optimized' but no reference or supporting study is cited; please add a reference or describe the optimization briefly.
  4. [Figure 6 (page 12)] The color maps in Figure 6 show H* values inside the body contour, but the text notes these are not meaningful. Please overlay a contour or blank out the region inside the body to avoid misreading.
  5. [Section 3.5 (page 19)] The discussion of 35S and 40K states that after about ten days the main contributions come from these isotopes; given the half-life of 40K (1.25×10^9 y) and its activity of a few hundred Bq, the dose relevance is negligible, but this conclusion would be clearer if the activity values at ten days were reported explicitly.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: BNCT dose rates are computed with independent transport simulations and the safety conclusion is explicitly conditional on a stated benchmark.

full rationale

The paper's derivation is a self-contained comparison. The patient-activation H* rates are obtained by PHITS transport calculations on an ICRP-145 phantom, after a benchmark against MCNP, using an externally specified beam spectrum [3]; the 131I reference field is an independent simulation of 600 MBq in the thyroid. No quantity is fitted to the target conclusion. The final claim is explicitly qualified: 'patient activation does not pose a significant radiological concern based on the proposed figure of merit' and 'adopting this criterion adapted from nuclear medicine in current Italian regulation.' The criterion itself is openly introduced as an assumption ('It can reasonably be assumed that, below this threshold, contact with a treated patient is safely acceptable'), so the inference is a stated conditional, not a disguised restatement. Self-citations ([3], [10]) supply the beam spectrum and a nuclear half-life as inputs, and neither is the result being derived; the first is an external beam design input and the second is nuclear data. The paper even acknowledges the indicator needs future validation. Under the review rules, no circular step can be exhibited with a specific reduction.

Assumptions & free parameters 2 free parameters · 4 assumptions · 0 invented entities

The central claim depends on the choice of the 131I benchmark, the validity of the activation simulation, the phantom assumptions, and the beam model. No new physical entities are postulated. The free parameters are scenario choices rather than fitted quantities.

free parameters (2)
  • 600 MBq 131I reference activity = 600 MBq
    Taken from Italian Decree 101/2020 Annex XXV as the hospitalization threshold; selected by authors as the discharge criterion. Not fitted to patient data, but the safety conclusion is defined relative to it.
  • Observation time after irradiation = 15 minutes
    Chosen as the minimum patient stay; short-lived 24mNa (20 ms half-life) has fully decayed by this time, making the comparison more favorable.
assumptions (4)
  • ad hoc to paper Ambient dose rate below the 600 MBq 131I patient value implies safe discharge for a neutron-activated patient.
    Introduced in Section 2 as the proposed criterion; this equivalence is the paper's own definition, not an existing legal limit for neutron irradiation.
  • domain assumption PHITS+DCHAIN-SP activation predictions are accurate enough for the conclusions.
    Section 2.1: PHITS adopted after an MCNP/PHITS benchmark, but that benchmark covers only the 131I photon dose calculation, not neutron activation inventories.
  • domain assumption The ICRP-145 adult mesh phantom and the modified urine composition represent a BNCT patient.
    Section 2.1 and Table 1: the phantom is a reference adult; urine composition was manually edited to include S and Cl, which affects 35S and 38Cl production.
  • domain assumption The neutron beam spectrum and room geometry from the authors' previous design studies are representative of the planned ANTHEM beam.
    Section 2.2: 'The spectrum of the neutron beam irradiating the patient is described in [3]' with no independent verification in this paper.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy." pith.science (2026). https://pith.science/paper/C23SCZOK

@misc{pith2026250113053,
  author       = {Pith},
  title        = {Pith review of: Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/C23SCZOK}},
  note         = {Machine review of arXiv:2501.13053}
}
read the original abstract

Boron Neutron Capture Therapy (BNCT) is a form of radiotherapy based on the irradiation of the tumour with a low energy neutron beam, after the administration of a selective drug enriched in boron-10. The therapy exploits the high cross section of thermal neutron capture in boron, generating two low-range charged particles. The availability of accelerators able to generate high-intensity neutron beams via proton nuclear interaction is boosting the construction of new clinical centres. One of these is under development in Italy, using a 5 MeV, 30 mA proton radiofrequency accelerator coupled to a beryllium target, funded by the Complementary Plan to the Recovery and Resilience National Plan, under the project ANTHEM. The present study focuses on radiation protection aspects of patients undergoing BNCT, specifically on the activation of their organs and tissues. A criterion to establish the relevance of such activation after BNCT has been proposed. Based on the current Italian regulatory framework, the level of patient activation following BNCT treatment does not pose a significant radiological concern, even shortly after irradiation. Another aspect is the activation of patient's excretions, which can impact on the design of the building and requires a process for the discharge. The described study contributes to the radiation protection study for the ANTHEM BNCT centre in Italy.

Figures

Figures reproduced from arXiv: 2501.13053 by the authors.

Figure 1
Figure 1. Building plan of ANTHEM project facility for BNCT in Caserta, Italy. [PITH_FULL_IMAGE:figures/full_fig_p004_1.png] view at source ↗
Figure 2
Figure 2. Phantom particulars of: [a] head district,[b] thoracic district, [c] lower limbs. [PITH_FULL_IMAGE:figures/full_fig_p006_2.png] view at source ↗
Figure 3
Figure 3. Facility geometry in PHITS [a] and a particular of the treatment room [b]. [PITH_FULL_IMAGE:figures/full_fig_p007_3.png] view at source ↗
Figures from the paper (6 more)
Figure 4
Figure 4. Figure 4: Patient irradiation positions for cancers located in: neck-head region [a], thorax [PITH_FULL_IMAGE:figures/full_fig_p008_4.png]
Figure 5
Figure 5. Figure 5: H* rate in a radius of 1.2 m around the patient due to 600 MBq of [PITH_FULL_IMAGE:figures/full_fig_p010_5.png]
Figure 6
Figure 6. Figure 6: H* maps at 15 minutes after 1 hour [a] and 2 hours [b] of irradiation in the head [PITH_FULL_IMAGE:figures/full_fig_p013_6.png]
Figure 7
Figure 7. Figure 7: H* maps at 15 minutes after 1 hour [a] and 2 hours [b] of thorax irradiation. [PITH_FULL_IMAGE:figures/full_fig_p015_7.png]
Figure 8
Figure 8. Figure 8: H* maps at 15 minutes after 1 hour [a] and 2 hours [b] of lower limbs irradiation. [PITH_FULL_IMAGE:figures/full_fig_p018_8.png]
Figure 9
Figure 9. Figure 9: H* maps due to 131I administration [a] and due to 2 hours irradiation activation (after 15 minutes) for head [b], thorax [c], legs [d]. considerations as conservative as possible, the comparison was carried out with the 2 hours irradiation case, despite the irradiation…

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

14 extracted references · 14 canonical work pages

  1. [1]

    AA.VV., Advances in Boron Neutron Capture Therapy, TECDOC Se- ries, INTERNATIONAL ATOMIC ENERGY AGENCY, Vienna, 2023

    work page 2023

  2. [2]

    Pisent, E

    A. Pisent, E. Fagotti, P. Colautti, Munes a compact neutron source for bnct and radioactive wastes characterization, in: Proc. Linear Acceler- ator Conf. LINAC, 2014, pp. 261–263

    work page 2014

  3. [3]

    Postuma, S

    I. Postuma, S. Gonz´ alez, M. S. Herrera, L. Provenzano, M. Ferrarini, C. Magni, N. Protti, S. Fatemi, V. Vercesi, G. Battistoni, et al., A novel approach to design and evaluate bnct neutron beams combining 22 physical, radiobiological, and dosimetric figures of merit, Biology 10 (3) (2021) 174

    work page 2021

  4. [4]

    Esposito, P

    J. Esposito, P. Colautti, S. Fabritsiev, A. Gervash, R. Giniyatulin, V. Lo- masov, A. Makhankov, I. Mazul, A. Pisent, A. Pokrovsky, M. Rumyant- sev, V. Tanchuk, L. Tecchio, Be target development for the accelerator- based spes-bnct facility at infn legnaro, Applied Radiation and Isotopes 67 (7, Supplement) (2009) S270–S273

    work page 2009

  5. [5]

    C. H. Kim, Y. Yeom, N. Petoussi-Henß, M. Zankl, W. E. Bolch, C. Lee, C. Choi, T. T. Nguyen, K. Eckerman, H. Kim, et al., Icrp publication 145: adult mesh-type reference computational phantoms, Annals of the ICRP 49 (3) (2020) 13–201

    work page 2020

  6. [6]

    D. B. Pelowitz, et al., MCNP – A General Monte Carlo N-Particle Trans- port Code, Version 6.3, Los Alamos National Laboratory, Los Alamos, NM, lA-UR-23-10009 (2023)

    work page 2023

  7. [7]

    T. Sato, Y. Iwamoto, S. Hashimoto, T. Ogawa, T. Furuta, S. ichiro Abe, T. Kai, P.-E. Tsai, N. Matsuda, H. Iwase, N. Shigyo, L. Sihver, K. Niita, Features of particle and heavy ion transport code system (phits) version 3.02, Journal of Nuclear Science and Technology 55 (6) (2018) 684–690

    work page 2018

  8. [8]

    H. N. Ratliff, N. Matsuda, S. ichiro Abe, T. Miura, T. Furuta, Y. Iwamoto, T. Sato, Modernization of the dchain-phits activation code with new features and updated data libraries, Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Mate- rials and Atoms 484 (2020) 29–41

    work page 2020

Show all 14 references
  1. [9]

    AA.VV., Icru report 95: Operational quantities for external radiation exposure, Journal of the ICRU 20 (7) (2020)

    2020

  2. [10]

    C. Magni, Experimental and computational studies for an accelerator- based boron neutron capture therapy clinical facility: a multidisciplinary approach - phd thesis - university of pavia (2022)

    2022

  3. [11]

    Woodard, D

    H. Woodard, D. White, The composition of body tissues, The British journal of radiology 59 (708) (1986) 1209–1218

    1986

  4. [12]

    Suzuki, K

    S. Suzuki, K. Nitta, T. Yagihashi, P. Eide, H. Koivunoro, N. Sato, S. Gotoh, S. Shiba, M. Omura, H. Nagata, et al., Initial evaluation of 23 accelerator-based neutron source system at the shonan kamakura gen- eral hospital, Applied Radiation and Isotopes 199 (2023) 110898

    2023

  5. [13]

    Hirose, A

    K. Hirose, A. Konno, J. Hiratsuka, S. Yoshimoto, T. Kato, K. Ono, N. Otsuki, J. Hatazawa, H. Tanaka, K. Takayama, et al., Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10b) for recurrent or locally advanced head and neck cancer (j...

    2021

  6. [14]

    Igaki, N

    H. Igaki, N. Murakami, S. Nakamura, N. Yamazaki, T. Kashihara, A. Takahashi, K. Namikawa, M. Takemori, H. Okamoto, K. Iijima, et al., Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: a report of two patients, Clinical and Translational Ra...

    2022

Pith tools

Reviewed August 10, 2026 · model on record in the stance chip above.